A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19
Status:
Completed
Trial end date:
2021-05-18
Target enrollment:
Participant gender:
Summary
The main purpose of this phase-1b, multicenter, randomized double-blind, placebo-controlled,
trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of
bempegaldesleukin (BEMPEG; NKTR-214) in combination with standard of care (SOC) in adult
patients with mild COVID-19 (coronavirus disease 2019). The trial will also define the
recommended phase 2 dose (RP2D) of bempegaldesleukin in patients with mild COVID-19.